Spermosens AB EBIT

The latest EBIT for SPERM.ST is $-9.5M as of June 2026. That compares with $-9.2M in the prior-year period — down 2.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Spermosens AB's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPERM.ST's EBIT moved from $-9.2M to $-9.5M — a 2.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Spermosens AB's operating scale or balance-sheet position.

Against its sector companies, SPERM.ST currently prints $-9.5M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Spermosens AB's growth, margins, and balance sheet.

A EBIT figure of $-9.5M for SPERM.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting SPERM.ST's EBIT ($-9.5M), review year-over-year change from $-9.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.